Consolidated Statements of Operations (USD $)	12 Months Ended		13 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
License revenue	$ 19,048	$ 0	$ 19,048
Costs and expenses:
Noncash stock expense associated with in-licensing agreement	16,578,000	297,000	16,875,000
Noncash compensation	455,809	0	455,809
Other research and development	3,994,182	30,283	4,024,465
Total research and development	21,027,991	327,283	21,355,274
General and administrative:
Noncash compensation	2,966,373	86,494	3,052,867
Other general and administrative	1,815,083	468,197	2,283,280
Total general and administrative	4,781,456	554,691	5,336,147
Impairment of in-process research and development	1,104,700	0	1,104,700
Total costs and expenses	26,914,147	881,974	27,796,121
Operating loss	(26,895,099)	(881,974)	(27,777,073)
Other (income) expense:
Interest income	(15,787)	0	(15,787)
Other income	(272,232)	0	(272,232)
Interest expense	905,744	7,097	912,841
Change in fair value of notes payable	(1,659,872)	0	(1,659,872)
Total other (income) expense	(1,042,147)	7,097	(1,035,050)
Loss before income taxes	(25,852,952)	(889,071)	(26,742,023)
Income taxes	330,000	0	330,000
Consolidated net loss	(26,182,952)	(889,071)	(27,072,023)
Net loss attributable to non-controlling interest	(8,110,233)	(35,997)	(8,146,230)
Net loss attributable to TG Therapeutics, Inc. and Subsidiaries	$ (18,072,719)	$ (853,074)	$ (18,925,793)
Basic and diluted net loss per common share (in dollars per share)	$ (1.38)	$ (0.44)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	13,113,758	1,926,198